Genentech, a subsidiary of Swiss pharmaceutical group Roche, announced plans to expand its U.S. manufacturing footprint with a $750 million investment in a new production facility at its existing site in Hillsboro, Oregon. The project marks a significant commitment to domestic capacity expansion amid ongoing supply chain and geopolitical considerations.
The new facility will complement Genentech’s existing operations in the state, where the company has maintained a presence for decades. The investment underscores Roche’s strategy to bolster local production capabilities in the U.S., a market that remains critical for the group’s global revenue base. The company did not provide a timeline for construction or operational commencement.
Genentech, headquartered in South San Francisco, is one of the largest biotechnology companies in the U.S., with a portfolio spanning oncology, immunology, and neuroscience. The expansion aligns with broader industry trends favoring increased domestic manufacturing resilience, particularly in high-value pharmaceutical sectors.
Roche has not disclosed whether the investment will be funded through existing cash reserves, debt, or a combination of financing instruments. The company’s decision follows similar capacity-building initiatives by peers in the pharmaceutical sector, which have accelerated in response to supply chain disruptions and regulatory incentives aimed at reducing reliance on offshore production.
